Literature DB >> 1399019

Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers.

P J Sessink1, K A Boer, A P Scheefhals, R B Anzion, R P Bos.   

Abstract

The occupational exposure to cyclophosphamide (CP), ifosfamide (IF), 5-fluorouracil (5FU), and methotrexate (MTX) of 25 pharmacy technicians and nurses from four departments of a hospital was investigated. Previously developed methods for the detection of exposure to some antineoplastic agents were validated. Exposure to CP, IF, 5FU, and MTX was measured by the analysis of these compounds in the environment (air samples and wipe samples from possible contaminated surfaces and objects). Contamination of the work environment was found not only on the working trays of the hoods and on the floors of the different rooms but also on other objects like tables, the sink unit, cleaned urinals and chamber pots, and drug vials and ampules used for preparation and packing of drugs. The gloves used during preparation of the drugs and during cleaning of the hoods were always contaminated. The uptake of CP or IF was determined by the analysis of both compounds in urine. CP or IF was detected in the urine of eight pharmacy technicians and nurses. The amounts ranged from less than 0.01 to 0.5 micrograms (median: 0.1 microgram). CP and IF were found not only in the urine of pharmacy technicians and nurses actively handling these compounds (n = 2) but also in the urine of pharmacy technicians and nurses not directly involved in the preparation and administration of these two drugs (n = 6). CP and IF were excreted during different periods ranging from 1.40 to 24.15h after the beginning of the working day, suggesting different times of exposure, different exposure routes, and/or interindividual differences in biotransformation and excretion rate for these compounds.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1399019     DOI: 10.1007/bf00381477

Source DB:  PubMed          Journal:  Int Arch Occup Environ Health        ISSN: 0340-0131            Impact factor:   3.015


  15 in total

Review 1.  ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs.

Authors: 
Journal:  Am J Hosp Pharm       Date:  1990-05

2.  Leukemia following chemotherapy for ovarian cancer.

Authors:  J M Kaldor; N E Day; F Pettersson; E A Clarke; D Pedersen; W Mehnert; J Bell; H Høst; P Prior; S Karjalainen
Journal:  N Engl J Med       Date:  1990-01-04       Impact factor: 91.245

3.  Urinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide.

Authors:  C T Evelo; R P Bos; J G Peters; P T Henderson
Journal:  Int Arch Occup Environ Health       Date:  1986       Impact factor: 3.015

4.  Occupational exposure to cyclophosphamide.

Authors:  M Hirst; S Tse; D G Mills; L Levin; D F White
Journal:  Lancet       Date:  1984-01-28       Impact factor: 79.321

5.  Recommendations for handling cytotoxic drugs in hospitals.

Authors:  M H Stolar; L A Power; C S Viele
Journal:  Am J Hosp Pharm       Date:  1983-07

6.  Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.

Authors:  J Pedersen-Bjergaard; J Ersbøll; H M Sørensen; N Keiding; S O Larsen; P Philip; M S Larsen; H Schultz; N I Nissen
Journal:  Ann Intern Med       Date:  1985-08       Impact factor: 25.391

7.  Limitations of the salmonella/mammalian microsome assay (Ames test) to determine occupational exposure to cytostatic drugs.

Authors:  U Friederich; F Molko; V Hofmann; D Scossa; D Hann; F E Würgler; H J Senn
Journal:  Eur J Cancer Clin Oncol       Date:  1986-05

8.  Exposure of hospital workers to airborne antineoplastic agents.

Authors:  A deWerk Neal; R A Wadden; W L Chiou
Journal:  Am J Hosp Pharm       Date:  1983-04

Review 9.  Occupational exposure to anticancer drug--potential and real hazards.

Authors:  M Sorsa; K Hemminki; H Vainio
Journal:  Mutat Res       Date:  1985-09       Impact factor: 2.433

10.  Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide.

Authors:  J F Haas; B Kittelmann; W H Mehnert; W Staneczek; M Möhner; J M Kaldor; N E Day
Journal:  Br J Cancer       Date:  1987-02       Impact factor: 7.640

View more
  36 in total

Review 1.  Drugs hazardous to healthcare workers. Evaluation of methods for monitoring occupational exposure to cytostatic drugs.

Authors:  P J Sessink; R P Bos
Journal:  Drug Saf       Date:  1999-04       Impact factor: 5.606

2.  Safe handling of parenteral cytotoxics: recommendations for ontario.

Authors:  Esther Green; Mary Johnston; Maureen Trudeau; Lisa Schwartz; Susan Poirier; Gail Macartney; Deborah Milliken
Journal:  J Oncol Pract       Date:  2009-09       Impact factor: 3.840

3.  Inhalation and dermal exposure to eight antineoplastic drugs in an industrial laundry facility.

Authors:  Wouter Fransman; Daan Huizer; Jochen Tuerk; Hans Kromhout
Journal:  Int Arch Occup Environ Health       Date:  2006-10-05       Impact factor: 3.015

4.  Mortality patterns among female nurses: a 27-state study, 1984 through 1990.

Authors:  L A Peipins; C Burnett; T Alterman; N Lalich
Journal:  Am J Public Health       Date:  1997-09       Impact factor: 9.308

5.  Evaluation of working practices and surface contamination with antineoplastic drugs in outpatient oncology health care settings.

Authors:  Bettina Kopp; Rudolf Schierl; Dennis Nowak
Journal:  Int Arch Occup Environ Health       Date:  2012-02-05       Impact factor: 3.015

6.  A probabilistic assessment of the impact of interventions on oncology nurses' exposure to antineoplastic agents.

Authors:  T Meijster; W Fransman; J van Hemmen; H Kromhout; D Heederik; E Tielemans
Journal:  Occup Environ Med       Date:  2006-03-21       Impact factor: 4.402

7.  Hazardous drug residue on exterior vial surfaces: evaluation of a commercial manufacturing process.

Authors:  Luci A Power; Paul J M Sessink; Kathy Gesy; Flay Charbonneau
Journal:  Hosp Pharm       Date:  2014-04

8.  Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device.

Authors:  Paul J M Sessink; Thomas H Connor; James A Jorgenson; Timothy G Tyler
Journal:  J Oncol Pharm Pract       Date:  2010-02-15       Impact factor: 1.809

9.  Validation of urinary excretion of cyclophosphamide as a biomarker of exposure by studying its renal clearance at high and low plasma concentrations in cancer patients.

Authors:  Maria Hedmer; Peter Höglund; Eva Cavallin-Ståhl; Maria Albin; Bo A G Jönsson
Journal:  Int Arch Occup Environ Health       Date:  2007-06-20       Impact factor: 3.015

10.  Occupational exposure to cytotoxic drugs in two UK oncology wards.

Authors:  E Ziegler; Howard J Mason; P J Baxter
Journal:  Occup Environ Med       Date:  2002-09       Impact factor: 4.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.